While cost discipline improved non-GAAP losses and extended cash runway, the lack of revenue growth and continued net losses raise sustainability concerns. Upcoming 2026 clinical data readouts for vispa-cel and CB-011 will be critical catalysts. Investors should monitor whether Caribou secures additional funding ahead of the vispa-cel pivotal trial.
Price Chart
Executive Summary
Caribou Biosciences reported fourth quarter and full-year 2025 financial results, highlighting clinical progress in its two allogeneic CAR-T programs, vispa-cel and CB-011, with upcoming data readouts expected in 2026. Revenue increased modestly, while R&D and G&A expenses declined due to workforce reductions and pipeline prioritization. The company reported a GAAP net loss of $148.1 million, including a $21.3 million non-cash impairment charge, and ended the year with $142.8 million in cash, sufficient to fund operations into 2H 2027.
Key Financial Metrics
Key Facts
- Licensing and collaboration revenue increased to $11.2 million in 2025 from $10.0 million in 2024.
- R&D expenses decreased to $109.4 million in 2025 from $130.2 million in 2024 due to cost-cutting measures.
- GAAP net loss was $148.1 million in 2025, slightly improved from $149.1 million in 2024.
- Non-GAAP net loss improved to $126.8 million in 2025 from $149.1 million in 2024, excluding $21.3 million in non-cash impairment charges.
- Cash, cash equivalents, and marketable securities declined to $142.8 million from $249.4 million at year-end 2024.
- Company expects cash runway into 2H 2027 but is exploring options to fully fund the planned vispa-cel pivotal trial.
- Longer follow-up data from ANTLER trial and initial dose expansion data for CB-011 expected in 2026.
Financial Impact
Revenue up 12% YoY to $11.2M; operating expenses down $17.1M; cash burn of $106.6M in 2025; $21.3M non-cash impairment charge.
Risk Factors
- High cash burn and declining cash reserves despite cost-cutting; may require dilutive financing.
- Reliance on upcoming clinical data to validate 'best-in-class' claims without head-to-head trials.
- Forward-looking statements carry significant risk given early-stage pipeline and regulatory uncertainty.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3250668 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Jun 11, 2026 16w ago | 8-K | $1.66 $1.94 | ▲ +16.87% | ▲ +14.98% | $1.22 (−26.51%) |
Jun 11, 2026 16w ago | Press Release | $1.66 $1.94 | ▲ +16.87% | ▲ +14.98% | $1.22 (−26.51%) |
Jun 5, 2026 17w ago | DEFA14A | $1.84 $1.83 | ▼ −0.54% | ▼ −2.17% | $1.22 (−33.70%) |
Apr 24, 2026 23w ago | DEFA14A | $2.13 $2.16 | ▲ +1.41% | ▼ −3.55% | $1.22 (−42.72%) |
Mar 5, 2026 30w ago | 8-K | $1.82 $1.95 | ▲ +7.14% | ▲ +9.19% | $1.22 (−32.97%) |
Mar 5, 2026 30w ago | Press Release | $1.82 $1.95 | ▲ +7.14% | ▲ +9.19% | $1.22 (−32.97%) |
Feb 28, 2026 30w ago | Institutional Cluster | $1.84 $1.72 | ▼ −6.52% | ▲ +1.42% | $1.22 (−33.70%) |
Feb 24, 2026 31w ago | Insider Cluster | $2.14 $1.82 | ▼ −14.95% | ▼ −9.97% | $1.22 (−42.99%) |
Feb 24, 2026 31w ago | Insider Cluster | $2.14 $1.82 | ▼ −14.95% | ▼ −9.97% | $1.22 (−42.99%) |
Feb 24, 2026 31w ago | Insider Cluster | $2.14 $1.82 | ▼ −14.95% | ▼ −9.97% | $1.22 (−42.99%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access